GENSIGHT BIOLOGICS S.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4075 EUR | -3.44% |
|
+1.88% | -11.41% |
| Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
| Mar. 25 | GenSight: share price falls, limited financial visibility | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives.
At the end of 2022, the company had a portfolio of 2 products, including 1 in phase III clinical development (Lumevoq for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).
Calendar
2024-05-28
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.422
EUR
Average target price
0.4
EUR
Spread / Average Target
-5.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.41% | 35.07M | |
| -3.12% | 102B | |
| +2.21% | 96.84B | |
| -0.06% | 21.48B | |
| -18.35% | 20.82B | |
| -7.35% | 18.6B | |
| -40.70% | 16.81B | |
| -25.14% | 13.78B | |
| +1.37% | 13.4B | |
| +22.49% | 11.06B |
- Stock Market
- Equities
- SIGHT Stock
- News GenSight Biologics S.A.
- Gensight Biologics Secures Six-month Extension To Submit Response To Eye Therapy Review's Regulatory Concerns
